Literature DB >> 29290518

Enteral nutrition improves clinical outcome and reduces costs of acute mesenteric ischaemia after recanalisation in the intensive care unit.

Shuofei Yang1, Jianming Guo2, Qihong Ni3, Jiaquan Chen4, Xiangjiang Guo5, Guanhua Xue6, Meng Ye7, Lan Zhang8.   

Abstract

BACKGROUND: Little data evaluate the enteral nutrition (EN) for patients with acute mesenteric ischaemia (AMI) in the intensive care unit (ICU). This study assessed the outcomes of EN for recanalised AMI patients in the ICU.
METHODS: In this retrospective study, 183 AMI patients with mesenteric recanalisation admitted to two surgical ICUs were included. Patients were divided into EN (EN within first week, n = 95) and total parenteral nutrition (TPN) group (TPN in 1st week, n = 88). The etiology, outcomes and complications were compared. Nutritional, immunologic, inflammatory response and mesenteric reperfusion were evaluated. Subgroup analysis and cost-assessment were performed.
RESULTS: No significant difference of demographics and illness severity at baseline were found. The rates of TPN for ≥6 months (7.4% vs. 18.2%, P < 0.01), infectious complications (7.4% vs. 20.5%, P = 0.01) and acute respiratory distress syndrome (4.2% vs. 13.6%, P < 0.01) were lower in EN group. For patients with mesenteric infarction (n = 101), EN was associated with earlier bowel continuity restoration (P < 0.01) and lower 30-day mortality (7.3% vs. 26.1%, P = 0.01). For patients without initial bowel resection (n = 82), length of ICU and hospital stay was significantly shortened in EN group. The 1-year survival was 88.4% in EN group and 78.4% in TPN group (P = 0.031). EN was cost-effective, with improved inflammatory response and elevated peak velocity of mesenteric flow.
CONCLUSIONS: For recanalised AMI patients, EN starting within the first week represents a favourable alternative to TPN. A multicentre randomised controlled trial with high level of evidence is warranted in the future. CLINICAL RELEVANCY STATEMENT: Acute mesenteric ischaemia (AMI) is a catastrophic abdominal vascular emergency in the surgical intensive care unit (ICU), and the mortality of AMI remains unchanged despite significant progress of endovascular techniques. A multidisciplinary and multimodal management approach of AMI in the ICU has been recently proposed to improve patient's survival and prevent the intestinal failure. Post-recanalisation nutrition therapy may significantly improve the overall survival of AMI patients is quite underemphasised in the ICU. Definitive data comparing EN with TPN for this patient population are very lacking. This study provides the clinical data to suggest that early EN starting after ICU admission represents a favourable alternative to TPN for recanalised AMI patients. The nutrition therapy protocol in the ICU for this special cohort needs to be updated with more high-level evidence in the future.
Copyright © 2017 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  Acute mesenteric ischemia; Critical care; Endovascular recanalization; Enteral nutrition; Intestinal infarction

Mesh:

Year:  2017        PMID: 29290518     DOI: 10.1016/j.clnu.2017.12.008

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  3 in total

1.  Enteral nutrition provides favorable postoperative outcomes for patients with pseudomyxoma peritonei: a retrospective study.

Authors:  Xuechun Kuang; Guie She; Yanhui Shi; Zhiyou Yang; Jun Li; Zhipeng Zhang
Journal:  Gland Surg       Date:  2022-05

2.  Risk factors of enteral feeding intolerance in severe acute pancreatitis patients: A protocol for systematic review and meta-analysis.

Authors:  Hongyun Fan; Chunchun Yang; Zhiying Duan; Xiaohui Huo; Yang Yang
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

3.  Effect of Surgical Technique on the Microstructure and Microcirculation of the Small Intestine Stump during Delayed Anastomosis: Multimodal OCT Data.

Authors:  E B Kiseleva; M G Ryabkov; M A Sizov; E L Bederina; A D Komarova; A A Moiseev; M V Bagryantsev; A N Vorobiev; N D Gladkova
Journal:  Sovrem Tekhnologii Med       Date:  2021-08-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.